New Biotech Offering Targets $426B Rare Disease Market

The rare disease drug space is growing fast-and so is investor interest. With exclusivity, pricing power and major M&A moves, the rare disease space is getting interesting. This company has the science and the experience.

ALNY
Alnylam Pharmaceuticals Inc
NASDAQ
456.35
Open 465.01 Prev Close 460.99
High 465.01 Low 448.47
Volume 969,069 Volume (Avg) 1,143
52 Week High 484.21 52 Week Low 205.87
Market Cap 59.8B PE Ratio

About Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

General

NameAlnylam Pharmaceuticals Inc
TickerALNY
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology
CurrencyUSD
CountryUSA
Fiscal Year EndDecember
Full Time Employees2,230

Highlights

Analyst Target468.88
Market Cap59,817,900,000
PEG Ratio-0.49
EBITDA-123,687,000

Share Stats

Shares Outstanding130,980,000
Shares Float125,530,000
Shares Short3,720,000
Insider Holdings379%
Institution Holdings99.07%

Highlights

Analyst Target468.88
Market Cap59,817,900,000
PEG Ratio-0.49
EBITDA-123,687,000

Valuation

Forward PE46.51
Price/Sales (Trailing 12 Mt.)24.54
Price/Book (Most Recent Quarter)240.96

Earnings

Most Popular

QuantumScape (QS) Stock Hit A New 52-Week High Today: What's Going On?

Shares of QuantumScape soared to a new 52-week high Friday, capping a week of significant gains.

What to Stream: Documentaries on John Candy and Victoria Beckham, Battlefield 6 and 'Family Guy'

Documentaries on comedian John Candy and pop artist-turned-fashion designer Victoria Beckham as well as a “Family Guy” Halloween special are some of the new television, films, music and games near you.

The Cross-Chain Giant Set for 1,000%+ Gains - Ad

As crypto markets surge, one multi-chain financial protocol is being targeted for massive institutional investment. Its transaction volume is skyrocketing across all major blockchains while its price remains suppressed as retail has yet to discover it - creating a coiled spring ready to release.

America Has A New No. 1 Beer — And It's Got Bud Light DNA

When it comes to beer in the United States, there's a new bestselling brand.

How To Earn $500 A Month From Steelcase Stock Ahead Of Q2 Earnings

Steelcase offers an annual dividend yield of 2.37% (40 cents a year). How can investors pocket a regular $500 monthly?

Elon's $25 Trillion Confession - Ad

Elon Musk: "Tesla will become a $25 trillion company." That would make Tesla 8x bigger than Apple today. How is that possible? He admits it's all thanks to this one AI breakthrough that will take AI out of our computer screens and manifest a 250x boom here in the real world.

3 Gold Mining Stocks Shine As Prices Hit Records

Gold mining stocks Anglogold Ashanti, Coeur Mining, and New Gold join the top 10% for quality as gold prices hit fresh highs.

Cathie Wood's Reshuffle Tuesday: Loads Up On AMD, Figma And Bullish, Trims Tempus AI

On Tuesday, Cathie Wood-led Ark Invest executed significant trades, including buying shares of Advanced Micro Devices Inc. (NASDAQ:AMD) and Bullish Inc. (NYSE:BLSH), while selling shares o

Biotech With Multiple Orphan Drugs Is Quietly Opening Its Doors - Ad

A promising biotech developing treatments for rare childhood brain diseases is opening a new raise. Its lead drug has fast-track status, orphan designations, is nearing Phase 2 and backed by a Global Integrator.

Bill Gates Backs Utah Geothermal Plant As Fervo Energy Targets 500 MW Capacity At Cape Station

Bill Gates and Breakthrough Energy support Fervo Energy's Cape Station project, aiming to generate 500 MW of geothermal power.

Trump files $15 billion defamation lawsuit against The New York Times

NEW YORK (AP) — President Donald Trump filed a $15 billion defamation lawsuit against The New York Times and four of its journalists on Monday, according to court documents.

Trump's $500B AI Initiative Created This Income Opportunity - Ad

Project Stargate isn't just about AI software - it's about the energy infrastructure making AI possible. Companies providing natural gas infrastructure are required to distribute most cash flow as dividends that could potentially pay $1,125 to $4,290 monthly. Market volatility doesn't matter.

Here's Novo Nordisk's First Oral Obesity Drug In Europe With Proven Heart Health Impact

EMA approved Rybelsus' label update after the SOUL trial showed it cuts heart attack, stroke, and death by 14% in high-risk type 2 diabetes patients.

It's 'do or die' for electric vehicle maker Rivian as it breaks ground on a $5 billion plant

ATLANTA (AP) — It seems like a terrible time to build an electric vehicle plant in the United States, but Rivian Automotive leaders say they're confident as the company starts on a $5 billion facility in Georgia.

Stop Gambling On AI Stocks - Collect Monthly Infrastructure Income Instead - Ad

Everyone's betting on which AI company dominates. Smart investors are collecting income from the infrastructure they all need. Every AI system requires massive electricity. Trump's $500B Project Stargate is accelerating the buildout. Its monthly income from what AI can't function without.

BlackRock Turns Popular Mutual Funds Into Global Equity ETFs

BlackRock turns two top mutual funds into active ETFs, giving investors global equity exposure and strategies to manage volatility.

Big Tech's energy-hungry data centers could be bumped off grids during power emergencies

HARRISBURG, Pa. (AP) — With the explosive growth of Big Tech's data centers threatening to overload U.S. electricity grids, policymakers are taking a hard look at a tough-love solution: bumping the energy-hungry data centers off grids during power emergencies.

AI Data Centers Need Germany's Worth Of Electricity By 2030 - Ad

International Energy Agency: AI will demand electricity of entire nations by 2030. Trump: "We're going to have to double or triple our electricity." You get paid $1,125 to $4,290 monthly every time AI systems need power. Not speculation - essential infrastructure income. Simple as buying a stock.

Crypto Is The Money For AI, Says Economist As Coinbase CEO Teases Stablecoin-Powered Transactions Between Agents

Renowned economist Alex Tabbarok described cryptocurrencies as the “money” for artificial intelligence on Tuesday after Coinbase Global Inc. (NASDAQ:COIN) CEO teased a new feature that enables AI agents to transact using stablecoins.

Australia warns social media platforms against age verification for all ahead of a ban on children

MELBOURNE, Australia (AP) — Australian authorities said Tuesday that should not demand age verification for all account holders starting from December, when a having accounts goes into effect in the country.

The Tesla Shock Nobody Sees Coming - Ad

While headlines scream "Tesla is doomed"...Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.

Ex-Trump Lawyer Raises Alarms: 'I Have Never Been As Concerned As To Whether Our System Can Withstand The Pressure'

Abbe Lowell, a lawyer who once represented President Donald Trump's family, has expressed grave concerns over the potential harm the current administration could cause to the country's institutions.

Charlie Kirk Raised $85 Million Last Year — Widow Vows to Continue His Work

The assassination of Turning Point USA founder Charlie Kirk at a Utah Valley University event on September 10 has cast a shadow of uncertainty over the future of his political and business ventures.

Crypto Meets Wall Street - Are You Ready? - Ad

The Hedge Fund Summit is bringing top minds from crypto and traditional finance together. Discover new strategies, insights, and connections that could shape your portfolio's future.

FDA proposes ban on Orange B, a food dye not used for decades

Federal regulators are proposing to remove another from the U.S. food supply — Orange B, a synthetic color that hasn't been used in the U.S. for decades.

The "Mar-A-Lago Accord" Is Now Underway - Ad

The global order is in chaos. And according to 40-year market veteran Dr. David Eifrig, the biggest controlled demolition of the old monetary order in history could now be here, too. That means if you don't take action today, your wealth could decline by 40%... (Yes, even your cash savings.)

Republicans unveil a bill to fund the government through Nov. 21. Democrats call it partisan

WASHINGTON (AP) — House Republicans unveiled Tuesday a stopgap spending bill that would keep federal agencies funded through Nov. 21, daring Democrats to block it knowing that the fallout would likely be a partial government shutdown that would begin Oct. 1, the start of the new budget year.

Earnings This Week: Micron's Moment, Costco On Deck

Two very different stories… one riding the AI wave, the other proving steady compounding still wins.

New Biotech Offering Targets $426B Rare Disease Market - Ad

The rare disease drug space is growing fast-and so is investor interest. With exclusivity, pricing power and major M&A moves, the rare disease space is getting interesting. This company has the science and the experience.

FDA takes aim at Hims and other telehealth services in drug advertising blitz

WASHINGTON (AP) — For the first time, federal health officials are taking aim at promoting unofficial versions of prescription drugs — including popular weight loss medications — as part of the on pharmaceutical advertising.

Jury awards $205M to the parents of a girl who fell to her death at a Colorado amusement park

DENVER (AP) — A jury has awarded $205 million to the parents of a 6-year-old girl at a Colorado amusement park after she wasn't strapped in to a ride.

The Cross-Chain Giant Set for 1,000%+ Gains - Ad

As crypto markets surge, one multi-chain financial protocol is being targeted for massive institutional investment. Its transaction volume is skyrocketing across all major blockchains while its price remains suppressed as retail has yet to discover it - creating a coiled spring ready to release.

Elizabeth Warren Says Measles Can Hit Record Highs, Slams RFK Jr.'s CDC Panel For Delaying Vaccine: 'How Does That Keep Our Kids Safe?'

Sen. Elizabeth Warren (D-Mass.) on Thursday criticized the Centers for Disease Control and Prevention's vaccine advisory panel following its controversial vote to delay the combined measles, mumps, rubella, and varicella or MMRV vaccine for children under 4 years old.

Elon's $25 Trillion Confession - Ad

Elon Musk: "Tesla will become a $25 trillion company." That would make Tesla 8x bigger than Apple today. How is that possible? He admits it's all thanks to this one AI breakthrough that will take AI out of our computer screens and manifest a 250x boom here in the real world.

Australian bank ANZ agrees to pay record $160M penalty for corporate misconduct

MELBOURNE, Australia (AP) — One of Australia’s largest banks said Monday it agreed to pay a record 240 million Australian dollars ($160 million) in penalties for corporate misconduct affecting almost 65,000 customers and the federal government.

Republican leaders reject Democratic health care demands for bill to avoid shutdown

WASHINGTON (AP) — Republican leaders in the House and Senate said Wednesday that they will reject for an immediate , challenging Democrats to vote against a stopgap spending bill that doesn't include them but will keep the government open at the end of the month.

Biotech With Multiple Orphan Drugs Is Quietly Opening Its Doors - Ad

A promising biotech developing treatments for rare childhood brain diseases is opening a new raise. Its lead drug has fast-track status, orphan designations, is nearing Phase 2 and backed by a Global Integrator.

Hillary Clinton Says Trump Administration Is 'Going Great' For The President, Dogecoin Rallies 20%, Silver Token Tops Bitcoin — This Week In Crypto

The past week has been a rollercoaster ride in the world of finance and politics. From silver-backed cryptocurrencies outperforming Bitcoin (CRYPTO: BTC) to Hillary Clinton’s accusations of crypto corruption against the Trump administration, there’s been no shortage of headlines.

Most Recent

Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.

Copyright systemtrading.ca
Privacy Policy | Terms of Service